CHEK2 and neoplasm: Patients with alterations in ATM, BARD1, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, NBN, PALB2, RAD51, RAD51B, RAD51C, RAD51D or RAD54L detected in tissue, or ATM, BRCA1 or BRCA2 in plasma, are eligible for the TRITON2 study, while GALAHAD is only enrolling men with biallelic tumour alterations in ATM, BRCA1, BRCA2, BRIP1, CHEK2, FANCA, HDAC2 or PALB2 detected in circulating free DNA.